Drug Profile
Danburstotug - ImmuneOncia Therapeutics
Alternative Names: IMC-001; STI-3031; STI-A1015Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer Asan Medical Center; ImmuneOncia Therapeutics; Sorrento Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - T-cell lymphoma
Highest Development Phases
- Phase III Cervical cancer
- Phase II Extranodal NK-T-cell lymphoma; Gastric cancer; Liver cancer; Oesophageal cancer
- Phase I Malignant melanoma; Solid tumours
Most Recent Events
- 15 Apr 2024 ImmuneOncia Therapeutics plans phase-II TMB-H trial for Solid tumours (Metastatic disease, Late-stage disease) in June 2024 (IV, infusion), (NCT06365840)
- 14 Apr 2023 Efficacy and adverse events data from a phase II NeoChance trial in oesophageal, gastric and liver cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 31 Mar 2023 Sorrento Therapeutics withdraws a phase II trial in Peripheral T cell lymphoma, Diffuse large B-cell lymphoma, Extranodal NK T cell lymphoma and Biliary tract cancer (Second line therapy or greater, Late-stage disease), prior to enrolment, as the company files for chapter 11 bankruptcy (NCT03999658)